Using guided imagery to reduce nausea and vomiting in children undergoing chemotherapy
Effect of Guided Imagery on Chemotherapy-related Nausea and Vomiting in Pediatric Oncology Patients: a Randomized Controlled Trial
This study is testing if using guided imagery can help reduce nausea and vomiting in children aged 7 to 18 who are receiving chemotherapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 7 Years to 18 Years |
| Sex | All |
| Sponsor | Baskent University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Ankara, Ankara) |
| Trial ID | NCT06120764 on ClinicalTrials.gov |
What this trial studies
This randomized controlled study aims to evaluate the effectiveness of guided imagery as an intervention for managing chemotherapy-induced nausea and vomiting in pediatric cancer patients. Participants aged 7 to 18 will be randomly assigned to receive either guided imagery along with routine care or routine care alone. The study will assess differences in nausea, vomiting, and vital signs between the two groups to determine the impact of the guided imagery technique. This approach seeks to enhance the quality of life for children undergoing chemotherapy by providing a non-pharmacological method to alleviate distressing symptoms.
Who should consider this trial
Good fit: Ideal candidates are children aged 7 to 18 who are receiving intravenous chemotherapy with a high or moderate risk of nausea and vomiting.
Not a fit: Patients receiving radiotherapy or those taking supplements to reduce nausea may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly improve the quality of life for pediatric cancer patients by reducing chemotherapy-related nausea and vomiting.
How similar studies have performed: While guided imagery has been explored in various contexts, this specific application in pediatric oncology is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 7 to 18 years old, * who will receive intravenous chemotherapy, * no cognitive or neurological disease that would prevent communication, * receiving a chemotherapy protocol with a high or moderate emetogenic effect according to the MASCC/ESMO Antiemetic Guideline Classification, * no verbal, visual and auditory communication disabilities (ability to speak Turkish, no mental deficiency), * children whose parents and themselves volunteered to participate in the study Exclusion Criteria: * Children receiving radiotherapy, * taking ginger powder or vitamins to reduce nausea, * children who did not want to participate in the study
Where this trial is running
Ankara, Ankara
- Hacettepe University İhsan Doğramacı Hospital — Ankara, Ankara, Turkey (Türkiye) (Recruiting)
Study contacts
- Principal investigator: Ayşe Ay, RN, PhD — Baskent University
- Study coordinator: Ayşe Ay, RN, PhD
- Email: ayse0526@gmail.com
- Phone: +905073560214
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.